ProCE Banner Activity

Selecting Patients for PARP Inhibitor Therapy: Principles of Genetic Testing

Slideset Download
Download these slides from a live symposium for an expert review of optimal genetic testing in prostate cancer, from selection of patients with mCRPC for treatment with PARP inhibitors to implications of cascade testing for family members.

Released: February 23, 2022

Expiration: February 22, 2023

No longer available for credit.

Share

Faculty

Heather H. Cheng

Heather H. Cheng, MD, PhD

Associate Professor
Department of Medicine (Hematology and Oncology)
University of Washington
Division of Clinical Research
Fred Hutchinson Cancer Center
Seattle, Washington

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme Corp.

Pfizer, Inc.

Faculty Disclosure

Primary Author

Heather H. Cheng, MD, PhD

Associate Professor
Department of Medicine (Hematology and Oncology)
University of Washington
Division of Clinical Research
Fred Hutchinson Cancer Center
Seattle, Washington

Heather H. Cheng, MD, PhD, has disclosed that she has received consultant/advisor/speaker fees from AstraZeneca and funds for research support from Astellas, Clovis, Color Genomics, Janssen, Medivation, Phosplatin, and Sanofi.